Early haemorrhagic morbidity and mortality during remission induction with or without all‐trans retinoic acid in acute promyelocytic leukaemia
Open Access
- 29 March 2000
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 108 (4), 689-695
- https://doi.org/10.1046/j.1365-2141.2000.01936.x
Abstract
A total of 622 consecutive patients with acute promyelocytic leukaemia (APL) treated within the Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA) group during 1989–97 have been reviewed to assess the clinical effectiveness of all‐trans retinoic acid (ATRA) on the incidence of early haemorrhagic deaths and on APL‐associated coagulopathy. Of them, 499 were treated with idarubicin plus ATRA (study A) and 123 with Idarubicin alone (study B). In both studies, similar guidelines for supportive treatment were used. Haemorrhagic symptoms were evaluated according to a reproducible score system. Deaths occurring within 10 d of starting treatment were 19 (3.8%) in study A and nine (7.3%) in study B (P = 0.09), with 15 (3%) and five (4.1%) (P not significant) due to haemorrhage. Overall, induction mortality was 7.6% and 16.2% respectively (P < 0.003). In study A, days with platelet counts ≤ 20 × 109/l or with fibrinogen ≤ 1 g/L were reduced by about 30%, the haemorrhagic score by 50% and the consumption of blood products by about 40%, and fewer patients were treated with antihaemorrhagic drugs (39% vs. 61%; P < 0.001). On multivariate analysis, early deaths were influenced by blast count at diagnosis > 30 × 109/l (P < 0.001) in both studies, and by a haemorrhagic score of 3 in study A (P < 0.001). Although the reduction of early fatal haemorrhages was not significant, a substantial clinical improvement was evident in terms of reduction of the severity of bleeding symptoms, blood product consumption and overall induction mortality when ATRA was combined with idarubicin.Keywords
This publication has 20 references indexed in Scilit:
- Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.Journal of Clinical Oncology, 1998
- All-trans-Retinoic Acid in Acute Promyelocytic LeukemiaNew England Journal of Medicine, 1997
- AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot studyBlood, 1996
- Significant reduction of medical costs by differentiation therapy withall-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemiaCancer, 1995
- All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group [see comments]Blood, 1995
- All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York StudyAnnals of Internal Medicine, 1994
- Four years' experience with the treatment of all‐trans retinoic acid in acute promyelocytic leukemiaAmerican Journal of Hematology, 1993
- Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)New England Journal of Medicine, 1991
- Idarubicin (4‐demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: A pilot study of the Italian cooperative group GIMEMAEuropean Journal of Haematology, 1990
- TRANEXAMIC ACID FOR CONTROL OF HAEMORRHAGE IN ACUTE PROMYELOCYTIC LEUKAEMIAThe Lancet, 1989